Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma-Reference-Cited by-同舟云学术

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

Published:2015-03-19 Issue:12 Volume:125 Page:1883-1889
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Duvic Madeleine¹,Pinter-Brown Lauren C.²,Foss Francine M.³,Sokol Lubomir⁴,Jorgensen Jeffrey L.¹,Challagundla Pramoda¹,Dwyer Karen M.⁵,Zhang Xiaoping⁵,Kurman Michael R.⁵,Ballerini Rocco⁵,Liu Li⁶,Kim Youn H.⁷

Affiliation:

1. MD Anderson Cancer Center, Houston, TX;

2. University of California, Los Angeles, CA;

3. Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT;

4. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;

5. Kyowa Hakko Kirin Pharma Inc, Princeton, NJ;

6. ReSearch Pharmaceutical Services, Inc, Fort Washington, PA; and

7. Stanford Cancer Center, Stanford, CA

Abstract

Key Points Mogamulizumab was well-tolerated in 41 patients with previously treated mycosis fungoides or Sézary syndrome. Durable responses observed with a global overall response rate of 36.8%; patients with Sézary syndrome had a response rate of 47.1%.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/12/1883/1382918/1883.pdf

Reference34 articles.

1. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).;Olsen;Blood,2007

2. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors.;Campbell;Blood,2010

3. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.;Agar;J Clin Oncol,2010

4. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas.;Quaglino;Cancer,2012

5. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.;Talpur;Clin Cancer Res,2012

Cited by 189 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides;Nature Communications;2024-01-25

2. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

3. Cutaneous T-cell lymphoma with CNS involvement: a case series and review of the literature;CNS Oncology;2023-12-01

4. A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom;Cancers;2023-11-30

5. Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma;Cancer Management and Research;2023-09